Invesco’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Invesco’s Portfolio EVFM Stock Details EVFM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-619,599	Closed	-$16.3M	–	4084
2021 Q1	$16.3M	Sell	619,599 -227,023	-27%	-$10.3M	﹤0.01%	1679
2020 Q4	$30.6M	Buy	846,622 +1,890	+0.2%	+$68.3K	0.01%	1212
2020 Q3	$29.9M	Hold	844,732	–	–	0.01%	1125
2020 Q2	$35.9M	Buy	844,732 +57,205	+7%	+$3.86M	0.01%	1046
2020 Q1	$62.8M	Hold	787,527	–	–	0.03%	695
2019 Q4	$72.9M	Hold	787,527	–	–	0.02%	821
2019 Q3	$59.5M	Hold	787,527	–	–	0.02%	910
2019 Q2	$78.4M	Buy	787,527 +148,148	+23%	+$11.5M	0.02%	794
2019 Q1	$33.6M	Buy	639,379 +28,369	+5%	+$1.54M	0.01%	986
2018 Q4	$38.4M	Hold	611,010	–	–	0.01%	876
2018 Q3	$37.1M	Hold	611,010	–	–	0.01%	970
2018 Q2	$24.8M	Buy	611,010 +141,843	+30%	+$11.2M	0.01%	1115
2018 Q1	$44.7M	Buy	+469,167	New	+$60.2M	0.02%	789

Other funds holding EVFM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $486M AUM 50.29% 1-Year Est. Return

Invesco's EVFM Position: Q2 2021 in Review

Invesco sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q2 2021, closing a stake of 619,599 shares — an estimated $16.3M sold.

Invesco first reported a position in EVFM in Q1 2018 and held it in 13 quarters. The position peaked at $78.4M in Q2 2019. 82 funds tracked by Wall St. Rank hold EVFM as of Q2 2021.

Invesco reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
Invesco sold 619,599 Evofem Biosciences, Inc. Common Stock shares in Q2 2021, an estimated $16.3M.
Invesco first reported a position in Evofem Biosciences, Inc. Common Stock in Q1 2018 and held it in 13 quarters.
Invesco's Evofem Biosciences, Inc. Common Stock position peaked at $78.4M in Q2 2019.
82 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q2 2021.

Based on Invesco's 13F filing for Q2 2021, filed 17 Aug 2021.